Changes in obesity-related diseases and biochemical variables after laparoscopic sleeve gastrectomy: a two-year follow-up study by Våge, Villy et al.
Våge et al. BMC Surgery 2014, 14:8
http://www.biomedcentral.com/1471-2482/14/8RESEARCH ARTICLE Open AccessChanges in obesity-related diseases and
biochemical variables after laparoscopic sleeve
gastrectomy: a two-year follow-up study
Villy Våge1*, Vetle Aaberge Sande2, Gunnar Mellgren2,4, Camilla Laukeland1, Jan Behme1
and John Roger Andersen1,3Abstract
Background: To evaluate changes in obesity-related diseases and micronutrients after laparoscopic sleeve
gastrectomy (LSG).
Methods: We started the procedure in May 2007, and by December 2011, 117 patients could be evaluated for a
two year follow-up. Comparisons of preoperative status with 12 and 24 months postoperative status were made for
body mass index (BMI), obesity-related diseases and micronutrients.
Results: Major complications included bleeding requiring transfusion at 5.1%, leak at 1.7% and abscess without a
visible leak at 0.9%. Mean BMI was reduced from 46.6 (standard deviation (SD) 6.0) kg/m2 to 30.6 (SD 5.6) kg/m2 at
two years, and resolution occurred for 80.7% of patients with type 2 diabetes, 63.9% with hypertension, 75.8% with
hyperlipidemia, 93.0% with sleep apnea, 31.4% with musculoskeletal pain, 85.4% with snoring and 73.3% with
urinary incontinence. Amenorrhea resolved in all premenopausal females. The proportion of patients with
symptomatic gastroesophageal reflux disease increased from 12.8% to 27.4%. The prevalence of patients with low
ferritin-levels increased, while 25-hydroxyvitamin D (25(OH)D) deficiency decreased postoperatively.
Conclusions: LSG is an effective procedure for morbid obesity and obesity-related diseases, but the technique
should be further explored particularly to avoid gastroesophageal reflux.
Keywords: Sleeve gastrectomy, Obesity, Comorbidities, ComplicationsBackground
Between 1980 and 2008, the age-standardized mean glo-
bal body mass index (BMI) increased by 0.4–0.5 kg/m2
per decade in men and women [1], and worldwide obes-
ity more than doubled. Obesity, and particularly morbid
obesity (BMI ≥ 40) is known as a strong risk factor for
several diseases and premature death [2].
Bariatric surgery is the only evidence-based treatment
of morbid obesity with proven, sustained weight loss and
improvement in comorbidities [3-5]. Laparoscopic sleeve
gastrectomy (LSG) was introduced as the first stage in a
two-staged bariatric surgical approach on super-obese or
high-risk patients [6], but has now gained acceptance as
a stand-alone bariatric procedure [7-11]. Physiologically* Correspondence: villy.vage@helse-forde.no
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reproduction in any medium, provided the orit is an attractive procedure because it reduces the gas-
tric volume while preserving the continuity of the
gastrointestinal tract. Data on complications and weight
loss after LSG have been increasingly published in the
surgical literature, but data for the effects on comorbidi-
ties and micronutrients should be further explored
[12,13].
Our bariatric surgical program started in 2001 with
open Biliopancreatic diversion with duodenal switch
(BPDDS), and LSG as a stand-alone procedure was
started in May 2007. We had no experience with laparo-
scopic bariatric surgery prior to May 2007, and this pro-
spective study reviews our first patients focusing on
procedure complications, comorbidity resolution and
changes in biochemical variables at 12 and 24 months
postoperatively.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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After having obtained written informed consent from the
patients, data was prospectively collected and stored in our
database from the first LSG in May 2007 when LSG was
introduced as a part of our standard bariatric program.
The database is part of our continuous surveillance-
program and approved by the Norwegian Data Inspector-
ate. This present study is a prospective cohort study with
data extracted from the database. By December 2011 we
had 117 patients eligible for a two year follow-up. Indica-
tions for LSG were either a BMI ≥ 40 kg/m2 or a BMI ≥ 35
kg/m2 with obesity-related diseases. Contraindications for
operation were alcohol or drug abuse and active psychosis.
Preoperative evaluation and care included a one day
seminar with information about morbid obesity, bariatric
surgery and its risks, and estimated results as well as
projected possibilities about life changes after surgery.
This was followed by an individual consultation with the
bariatric surgeon and other health-personnel if needed.
Preoperative advice included smoking cessation, in-
creased physical activity and weight loss.
On the evening before the operation all patients received
low molecular weight heparin subcutaneously (enoxa-
parin), 40 mg if < 160 kg or 60 mg if ≥ 160 kg, and an H2
blocker (cimetidine 300 mg) orally. Intravenous antibiotic
prophylaxis (400 mg doxycycline, 1.5 g metronidazole)
was started just prior to the operation. The operation was
performed through six ports. Pneumoperitoneum was
established through the upper part of the left rectal sheet
using a 10 mm port containing the camera and the CO2-
insufflator. A 15 mm port was introduced at the same
level through the right rectal sheet. Four 5 mm ports were
used: One at the right subcostal area, one just below the
xiphoid process and two towards the left subcostal area.
All ports were reusable (Karl Storz™) except for the 15
mm port which was non-reusable (Ethicon™).
The greater curvature was freed from the pylorus to
the cardia, dividing all vessels by Ligasure (Covidien™).
To ensure a good overview of the left crus and the gas-
tro esophageal junction the periesophageal fat-pad was
generally freed from both the diaphragm and the cardia.
The stomach was divided along a 32 Fr bougie by the
Tri-Stapler (Covidien™) from 1-2 cm proximal to the pyl-
orus to the cardia. Over-sewing of the staple line was
performed for visible bleeding. Attention was paid to
avoid twisting or otherwise disrupting the gastric tube.
The resected part of the stomach was removed without
a bag through the incision for the 15 mm port. The ab-
dominal fascia at this point was closed by two Polydiox-
anon (PDS) number 1 sutures. All skin-incisions were
closed by intracutaneous reabsorbable sutures. Patients
were allowed to drink freely from the first postoperative
day, and discharged when tolerating a liquid diet. The
enoxaparin was continued for ten days after discharge.Postoperative advice included a low carbohydrate -
high protein diet, intake of one multivitamin tablet daily,
high frequency of water intake and physical activity. The
first 61 patients were also routinely recommended to take
Calcigran Forte (NycoMed Pharma™) containing one
gram of calcium carbonate and 800IE 25-hydroxyvitamin
D (25(OH)D) daily. Controls and data collection took
place at the outpatient clinic 3, 12 and 24 months post-
operatively. In addition, the patients were advised to see
their general practitioner at 6 and 18 months. Pregnancy
was strongly discouraged during the first 12 months after
the operation.
Surgical complications were defined as complications
occurring within 90 days after the surgical procedure.
Obesity-related diseases were defined as diseases that
were under medical care, and considered resolved when
the patient no longer needed medical care for the actual
disease (dichotomous variables). Diseases evaluated were
type 2 diabetes mellitus (T2DM), hypertension, hyperlip-
idemia, sleep apnea, obstructive lung disease, musculo-
skeletal pain, anxiety, depression and gastroesophageal
reflux. In addition, obesity-related problems as snoring,
urinary leakage, amenorrhea and infertility were in-
cluded independently of whether the patient received
treatment or not. Infertility was defined as attempting to
get pregnant over a period of two years without success.
Biochemical variables were selected according to our
empirical experience, and were all analyzed by the Depart-
ment of Clinical Biochemistry at our hospital except for
the vitamin D-analyses (Hormone Laboratory, Haukeland
University Hospital). The biochemical variables were con-
verted into dichotomous variables, as either within the ref-
erence range or outside the reference range.
Statistical Package for the Social Sciences (SPSS) ver-
sion 19.0 was used to perform the statistical analysis.
Paired t- test was used in comparing paired means for
change in BMI, and the McNemar´s test was used for
categorical variables. Statistical significance was set con-
ventionally at p < 0.05.
Results
For the 117 patients studied (87 women and 30 men), the
mean weight prior to the operation was 135.6 kg ± 23.7 kg
(standard deviation (SD)), mean BMI 46.6 ± 6.0 kg/m2,
and mean age 40.3 ± 10.7 years (Table 1).
Complications
Major complications included bleeding (5.1%, n = 6), leak
(1.7%, n = 2) and abscess without a visible leak (0.9%, n = 1)
(Table 2). One patient had both bleeding and leak. The
two patients who had a leak were treated with nil by
mouth and a nasojejunal feeding tube for two and five
months respectively before it healed. Both leaks were at
the cardiac region. Two of the patients with bleeding had
Table 1 Overview of the patients (n = 117)
Variables Mean ± SD
Age (years) 40.3 ± 10.7
Sex (Women/Men) 87/30
Weight (kg) 135.6 ± 23.7
BMI (kg/m2) 46.6 ± 6.0
Operation time (min) 134.6 ± 27.5
Concurrent operations* 4
SD = Standard deviation. BMI = body mass index.
*Concurrent operations were cholecystectomi (2), appendectomy (1) and hiatal
hernia repair (1).
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no conversion of laparoscopic to open surgery and no
mortality.
Obesity-related diseases
LSG significantly lowered the BMI to 30.3 ± 5.9 kg/m2 and
30.6 ± 5.6 kg/m2 at 12 and 24 months respectively, and re-
solved obesity-related diseases (Table 3). At two years, the
remission-rate for Type 2 Diabetes Mellitus (T2DM) was
80.7%, hypertension 63.9%, hyperlipidemia 75.8%, sleep ap-
noea 93.0%, musculoskeletal pain 31.4%, snoring 85.4%
and urinary leakage 73.3%. Amenorrhea was resolved for
all premenopausal female patients with two years data. We
lacked two year data for three of our twelve patients with
preoperative amenorrhea. The prevalence of gastroesopha-
geal reflux disease (GERD) increased from 12.8% prior to
the operation to 27.4% at two years (p = 0.011).
Biochemical variables
Of the biochemical variables, ferritin was lowered while 25
(OH)-vitamin D, albumin and alanine amino transferase
(ALT) improved significantly postoperatively (Table 4). We
found a high prevalence of patients with Parathyroid hor-
mone (PTH) above reference-level both preoperatively and
postoperatively. Hemoglobin-, folic acid-, cobalamine-, 1,
25-dihydroxyvitamin D (1,25(OH)2D), alkaline phosphataseTable 2 90-day morbidity after surgery (n = 117)
Complications Patients, n (%)
Bleeding (given transfusion) 6 (5.1%)
Reoperated 2 (1.7%)
Leak 2 (1.7%)
Reoperated 0 (0%)
Abscess without leak 1 (0.9%)
Reoperated 0 (0%)
Minor complications:
Wound infection 3 (2.6%)
Incisional hernia 1 (0.9%)
Relaparoscopy for retained drain 1 (0.9%)(ALP), PTH and calcium levels did not change significantly
after the procedure but 87% of the patients were taking
vitamin and/or mineral supplements 24 months after the
operation (Table 5). There was no difference in the vitamin
or mineral status when comparing patients using sup-
plements (n = 83) with patients not using supplements
(n = 12) (chi-square test and t-test).
Discussion
In the present study we find LSG to have acceptable
morbidity-rates and to be an effective procedure for
weight loss and resolution of comorbidities. LSG had
high resolution rates for T2DM, hypertension, hyper-
lipidemia, sleep apnea, musculoskeletal pain, snoring,
urinary leakage and amenorrhea. The BMI and the preva-
lence of obesity-related diseases were stable between 12
and 24 months postoperatively. Between 85 and 90% of
patients were taking some kind of vitamin and/or mineral
supplement at follow-up.
In general, the reported complication rates for LSG are
low despite high surgical risks in this patient group [8].
Shi et. al. systematically reviewed major perioperative
complications for LSG and found a mean ± SD of 1.17 ±
1.86% for leaks and 3.57 ± 5.15% for bleeding respectively
[14]. In order to reduce our leak-rate we have become par-
ticularly careful not to use heat-creating instruments close
to the stomach wall at the cardia where both leaks oc-
curred. In an attempt to reduce bleeding, we have changed
our regime for prophylaxis against thrombosis in that the
prophylaxis is started postoperatively and at reduced dos-
age. Other measures that could influence the rate of
bleeding would be the use of different stapler cartridges
and buttress material. There is currently no clear consen-
sus on how the surgical technique is optimally performed
[14], which makes it even more important to continuously
evaluate the results at different centers.
We are only presenting resolution and not changes in
the degree of severity of the obesity-related diseases or
conditions, these results therefore represent an underre-
porting of the patients’ improvement. Remission rates for
T2DM, hypertension, hyperlipidemia and sleep apnea are
higher among our patients than among sleeve- and gastric
bypass operated patients in the study by Zhang et al., but
our gastroesophageal reflux-rate is also higher [12]. This
could be due to differences in the surgical technique as we
used a somewhat smaller boogie (32 versus 38/40 Fr), and
we start the resection closer to the pylorus. For infertility,
we observed a reduction in infertility rate of 55.0% at two
years, but as pregnancy was strongly discouraged for the
first 12 months after the operation, the study is dependent
on 36 months data for completion of the infertility data
according to the definition. The regain of a normal men-
strual cycle in all amenorrheic premenopausal females is
remarkable.
Table 3 Proportion of patients (%) with obesity-related diseases prior to, and at 12 and 24 months after laparoscopic
sleeve gastrectomy
Variable Preoperative 12 months 24 months P value
12 vs 0 months 24 vs 0 months 24 vs 12 months
No. with available data/total no. 117/117 116/117 109/117
BMI (kg/m2, mean ± SD) 46.6 ± 6.0 30.3 ± 5.9 30.6 ± 5.6 <0.001 <0.001 0.936
Treated for No. with disease/no. with available data (%)
T2DM 23/117 (19.7%) 5/114 (4.4%) 4/105 (3.8%) <0.001 <0.001 1
Hypertension 50/117 (42.7%) 17/111 (15.3%) 16/104 (15.4%) <0.001 <0.001 1
Hyperlipidemia 14/117 (12.0%) 5/114 (4.4%) 3/104 (2.9%) 0.039 0.021 1
Sleep apnea 15/117 (12.8%) 3/116 (2.9%) 1/109 (0.9%) <0.001 <0.001 0.5
Obstructive lung disease 19/117 (16.2%) 19/114 (16.7%) 13/105 (12.4%) 1 0.063 0.063
Musculoskeletal pain 41/115 (35.7%) 29/114 (25.4%) 26/106 (24.5%) 0.067 0.026 0.804
Anxiety 18/117 (15.4%) 13/113 (11.5%) 11/103 (10.7%) 0.219 0.375 1
Depression 25/117 (21.4%) 18/113 (15.9%) 15/103 (14.6%) 0.109 0.125 1
GERD 15/117 (12.8%) 34/112 (30.4%) 29/106 (27.4%) 0.001 0.011 0.629
Suffering from (treated or not)
Snoring 89/114 (78.1%) 28/112 (25%) 13/102 (12.8%) <0.001 <0.001 0.002
Premenopausal/total no. of women 71/87 67/87 63/87
Urinary leakage 33/87 (37.9%) 11/84 (13.1%) 8/79 (10.1%) <0.001 <0.001 0.453
Amenorrhea 12/70 (17.1%) 3/65 (4.6%) 0/51 (0%) 0.021 0.016 1
Infertility 12/70 (17.1%) * 4/52 (7.7%) 0.180
BMI = Body mass index. SD = Standard deviation. No = Number. T2DM = Type 2 diabetes mellitus. GERD = Gastroesophageal reflux disease.
*Pregnancy was strongly discouraged during the first 12 months. At 24 months, two of the 12 women defined as infertile preoperatively had given birth to two
healthy children.
Table 4 Proportion of patients (%) with important biochemical variables below or above reference value prior to, and
at 12 and 24 months after laparoscopic sleeve gastrectomy
Variable Preoperative 12 months 24 months P value
12 vs. 0 months 24 vs. 0 months 24 vs. 12 months
No. with available data/total no: 95-117/117 98-107/117 65-95/117
No. below or above reference/no with available data (%)
Hb<ref. (11,5-16,0 g/dl) 7/117 (6%) 5/105 (4.8%) 4/95 (4.2%) 1 1 1
Ferritin<ref. (25-300 ug/l) 13/116 (11.2%) 20/101 (19.8%) 28/85 (32.9%) 0.021 0.001 0.118
Folic acid<ref. (> 5 nmol/l) 8/106 (7.5%) 8/100 (8.0%) 2/91 (2.2%) 1 0.453 0.125
Cobalamin<ref. (145–540 pmol/l) 4/111 (3.6%) 7/107 (6.5%) 3/94 (3.2%) 0.508 1 0.727
25(OH)D<ref. (30-150 nmol/l) 29/110 (26.4%) 5/105 (4.8%) 8/79 (10.1%) <0.001 <0.001 0.289
25(OH)D<50 nmol/l) 73/110 (66.4%) 39/105 (37.1%) 24/79 (30.4%) <0.001 <0.001 0.839
1,25(OH)2D>ref. (50-145 pmol/l) 0/104 (0.0%) 3/98 (3.1%) 1/65 (1.5%) 0.250 1 1
ALP>ref. (< 105 U/l) 6/116 (5.2%) 5/107 (4.7%) 7/94 (7.4%) 1 1 0.688
PTH>ref. (1.6-7.0 pmol/l) 35/95 (36.8%) 42/105 (40.0%) 36/85 (42.4%) 0.719 0.571 0.664
Calcium<ref. (2.15 – 2.55 mmol/l) 6/117 (5.1%) 1/108 (0.9%) 1/93 (1.1%) 0.124 0.125 1
Albumin<ref. (35-50 g/l) 16/117 (13.7%) 4/107 (3.7%) 8/94 (8.5%) 0.008 0.180 0.453
ALT>ref (35 U/l) 50/117 (42.7%) 11/107 (10.3%) 11/93 (11.8%) <0.001 <0.001 1
No = Number. Hb = Hemoglobin. Ref = Reference value. 25(OH)D = 25 hydroxyvitamin D. 1,25(OH)2D = 1,25 dihydroxyvitamin D. ALP = Alkaline Phosphatase.
PTH = Parathyroid hormone. ALT = Alanine aminotransferase.
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Table 5 Number of patients (%) using supplements prior
to, and at 12 and 24 months after laparoscopic sleeve
gastrectomy
Variable Preoperative 12 months 24 months
no. with available
data/total no:
115/117 107/117 96/117
No supplement 99 (86.1%) 16 (15.0%) 12 (12.5%)
Multivitamin 11 (9.6%) 79 (73.8%) 70 (72.9%)
Cobalamin 4 (3.5%) 26 (24.3%) 29 (30.2%)
Folic acid 5 (4.4%) 23 (21.5%) 18 (18.8%)
Calcium 2 (1.8%) 28 (26.2%) 35 (36.5%)
Iron 2 (1.8%) 3 (2.8%) 16 (16.7%)
No = Number.
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atically reviewed, finding both a significant increase and
a significant decrease in GERD after LSG [15]. Our
study shows a significant increase in GERD after the op-
eration, even though five of our fifteen patients who
were treated for GERD symptoms preoperatively had
resolution of their GERD symptoms postoperatively.
Our advice has been to have smaller meals at increased
frequency and consume foods at slower rates with suffi-
cient chewing, which might have some effect in reducing
GERD-symptoms as Melissas et. al. have also experi-
enced [16]. In accordance to the experience of Nocca
et. al. [17] it is also our experience that the patients with
GERD subjectively have a good effect of proton pump
inhibitors. Howard et. al. [18], who had a one year
GERD rate of 21.0%, declare that all of their GERD pa-
tients were “extremely happy with their surgery” and
“would choose the procedure again”. Despite Howard
et. al.´s findings, GERD is a potential drawback for the
LSG and more work is being done in order to reduce
the risk for GERD after LSG [15,19,20].
A high prevalence of micronutrient deficiencies among
morbidly obese prior to bariatric surgery has been ob-
served, a proposed consequence of malnutrition and/or
altered bioavailability to micronutrients due to reduced
dietary intake, reduced levels of hydrochloric acid and
intrinsic factor [21]. The number of patients with ferritin
levels below reference range in our data increased sig-
nificantly, similar to the findings of Himpens et. al. [22].
Himpens et. al. also found cobalamin deficiency one and
three years after LSG, which together with iron-related
deficiencies are the most common deficiencies after bar-
iatric surgery [22,23]. The number of patients with
cobalamin-deficiency was not altered in our study, but
27% and 29% of the patients were substituted with folic
acid or cobalamin respectively already one year after sur-
gery. Unfortunately, we do not know whether this sub-
stitution was based on low serum values for these
vitamins or not. Our findings highlight a need forfurther exploring the necessity of folic acid, cobalamin,
iron and possibly calcium-substitution in LSG patients
before making any general recommendations.
Values for albumin and ALT showed significant im-
provement after the operation, and ALT levels remained
significantly lowered at 24 months. Obesity is associated
with non-alcoholic fatty liver disease (NAFLD) [24], and
resolution of NAFLD has been proven after bariatric
surgery [25]. Improvement of liver-associated biochem-
ical variables due to resolution of NAFLD is therefore a
probable explanation of our finding.
LSG has been found to be equally as safe and effective
for weight loss and resolution of comorbidities as the
Roux-en-Y gastric bypass (RYGBP) in the short term
[12,23], and as the small bowel is not transected and no
mesenteric defects are created, the risk for long term
complications as jejunal ulcers and internal hernias are
avoided. Also, further conversion to BPDDS or RYGBP
if inadequate weight loss or weight regain should occur
makes LSG a good option among the bariatric proce-
dures. Long term effects of LSG are, however, still lim-
ited in terms of possible weight regain, side effects and
persistence of comorbidity resolution [14,17,26].
Conclusion
We find LSG to have acceptable morbidity-rates and to
be an effective procedure for weight loss and remission
of obesity-related diseases. Further development of the
technique should be attempted, particularly to reduce
the risk for postoperative gastroesophageal reflux.
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